1. Homepagina
  2. Aandelen
  3. Zweden
  4. NORDIC GROWTH MARKET
  5. EQL Pharma AB (publ)
  6. Nieuws
  7. Andere talen
    EQL   SE0005497732

EQL PHARMA AB (PUBL)

(EQL)
  Rapport
slotkoers NORDIC GROWTH MARKET  -  11-08-2022
31.60 SEK   -0.32%
13/05EQL Pharma AB (publ) Rapporteert Winstresultaten voor het Vierde Kwartaal en het Hele Jaar Eindigend op 31 Maart, 2022
CI
11/05EQL Pharma verleent uitlicentie voor Mellozzan aan H.A.C. Pharma in ADHD
CI
05/05EQL Pharma ontvangt goedkeuring voor Glycopyrronium EQL Pharma Oplossing voor Injectie 0,2Mg/Ml van Deens Geneesmiddelenbureau
CI
OverzichtKoersenGrafiekenNieuwsAgendaOndernemingFinanciŽn 
OverzichtAl het nieuwsAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op EQL PHARMA AB (PUBL)
11/07Invitation to presentation in connection with EQL Pharma's quarterly report, first quar..
08/07EQL PHARMA : Instruction for the Nomination Committee
08/07EQL PHARMA : Notice of annual general meeting on 17 August 2022
08/07Notice of annual general meeting in EQL Pharma AB
13/05Year-end Report April 2021 - March 2022
13/05EQL Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended March..
11/05EQL Pharma out-license Mellozzan to a leading French Company in ADHD
11/05EQL Pharma Out-License Mellozzan to H.A.C. Pharma in ADHD
05/05EQL Pharma get Glycopyrronium EQL Pharma approved
05/05EQL Pharma Receives Approval of Glycopyrronium EQL Pharma Solution for Injection 0.2Mg/..
26/04Invitation to presentation in connection with EQL Pharma's year-end report, fourth quar..
22/03EQL Pharma Out-licenses Mellozzan in Seven European Countries
22/03EQL Pharma out-license Mellozzan to a leading European Company in ADHD
22/03EQL Pharma out-license Mellozzan to a leading European Company in ADHD
04/03EQL Pharma's melatonin tablets approved in Denmark and Norway
03/03EQL Pharma donates 2500 bottles of Hevicain (bupivacaine) to Ukraine
16/02EQL PHARMA : Nterim report April-September 2021
16/02Interim Report April - December 2021
16/02EQL Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended Dece..
28/01Invitation to presentation in connection with EQL Pharma's quarterly report, third quar..
13/01EQL Pharma AB preliminarily announces very strong outcome for the third quarter and rep..
2021EQL Pharma receives SEK 23 million order for covid self-test
2021EQL Pharma Receives SEK 23 Million Order for Covid Self-Test
2021EQL Pharma Appoints New CFO
2021EQL Pharma appoints permanent CFO
2021EQL Pharma AB Appoints Anna Jönsson as Permanent Chief Financial Officer
2021Bulletin from the extraordinary general meeting in EQL Pharma AB on 10 December 2021
2021Notice of extraordinary general meeting in EQL Pharma AB
2021EQL Pharma CEO To Step Down In 2022, Successor Named
2021EQL Pharma will change CEO during 2022
2021EQL Pharma AB Announces CEO Changes
2021Interim Report April - September 2021
2021EQL Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended Sept..
2021EQL PHARMA : Invitation to presentation in connection with EQL Pharma's quarterly report, ..
2021EQL PHARMA : Latanoprost EQL Pharma Approved
2021EQL Pharma AB Announces Approval of Latanoprost Eql Pharma
2021EQL PHARMA : to exclusively launch first CE marked saliva based Covid-19 antigen self-test
2021EQL Pharma to Exclusively Launch First CE Marked Saliva Based Covid-19 Antigen Self-Tes..
2021EQL PHARMA : Receives Regulatory Approval for Nausea, Vomiting Treatment in Sweden
2021EQL PHARMA : Ondansetron EQL Pharma Approved
2021EQL PHARMA : Bulletin from the annual general meeting in EQL Pharma AB on 17 August 2021
2021EQL Pharma AB Announces Board Changes
2021EQL PHARMA : Interim Report April - June 2021
2021EQL Pharma AB Reports Earnings Results for the First quarter Ended June 30, 2021
2021EQL PHARMA : takes back Potassium Chloride rights in Denmark and Norway
2021EQL Takes Back Potassium Chloride Rights in Denmark and Norway
2021EQL PHARMA : Annual Report 2020/2021
2021EQL PHARMA : Invitation to presentation in connection with EQL Pharma's quarterly report, ..
2021EQL PHARMA : Notice of annual general meeting in EQL Pharma AB
2021EQL PHARMA : Mellozzan (melatonin) is now Reimbursed
2021EQL PHARMA : nbsp;Year-end Report April 2020 - March 2021
2021Eql Pharma AB Publ Reports Earnings Results for the Fourth Quarter Ended March 31, 2021
2021EQL PHARMA : to Sell Rapid COVID-19 Self-Testing Kits; Shares Up 32%
2021EQL PHARMA : distributes Europe's first CE marked SARS-CoV-2 self-test
2021EQL Pharma AB Distributes Sars-Cov-2 Self-Test
2021EQL PHARMA : Invitation to presentation in connection with EQL Pharma's quarterly report, ..
2021EQL PHARMA : Colecalciferol EQL Pharma Approval
2021EQL Pharma AB Receives Pharma Approval for Colecalciferol EQL
2021EQL PHARMA : Postpones Listing On Nasdaq Stockholm
2021EQL PHARMA : chooses to postpone the list change to Nasdaq Stockholm
2021EQL PHARMA : CFO has chosen to leave her position
2021EQL Pharma AB Announces Executive Changes
2021EQL PHARMA : becomes Nordic representative for Qilu Pharmaceuticals
2021EQL Pharma AB In-Licenses Seven Products for Denmark
2021EQL Pharma AB Announces Approval of Mellozzan
2021Eql Pharma AB Publ Reports Earnings Results for the Third Quarter Ended December 31, 20..
2021EQL Pharma AB Convenes Nomination Committee
2021EQL Pharma Announces Approval of Glucosparc
2020EQL Pharma Receives a New Order for Consumables from a Hospital Region
2020Eql Pharma AB Publ Reports Earnings Results for the Second Quarter Ended September 30, ..
2020EQL Pharma AB Announces approval of Granules for Oral Suspension 50Mg/Ml, 100Mg/Ml and ..
2020Eql Pharma AB Publ Reports Earnings Results for the First Quarter Ended June 30, 2020
2020Eql Pharma AB Publ Reports Earnings Results for the Fourth Quarter Ended March 31, 2020
2020EQL Pharma AB Revises Sales Guidance for the Year 2020
2020Eql Pharma AB Publ Reports Earnings Results for the Third Quarter Ended December 31, 20..
1  2Volgende
Volgende evenement op EQL PHARMA AB (PUBL)